查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835358

介入性肿瘤学市场：按产品类型、癌症类型、技术和最终用户划分－2025 年至 2032 年全球预测

Interventional Oncology Market by Product, Cancer Type, Technology, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年介入性肿瘤学市场将成长 45.8 亿美元，复合年增长率为 7.58%。

主要市场统计数据
基准年2024年 25.5亿美元
预计2025年 27.3亿美元
预测年份：2032年 45.8亿美元
复合年增长率（%） 7.58%

目前介入肿瘤学生态系统的权威说明

在技​​术创新、先进技术和日益增多的微创、器官保留治疗证据的推动下，介入肿瘤学已成为多学科癌症治疗的重要支柱。本介绍将重点介绍靶向器械的研发、影像学的增强以及在各种肿瘤类型中日益增长的临床接受度，从而描绘出更广阔的前景。近年来，临床医师已将消融和栓塞方法整合到治疗流程中，利用更精准的器械和更完善的围手术期工作流程来降低发病率，同时维持肿瘤控制。

此外，该行业正面临日益复杂的营运环境，这受到监管审查、供应链重组和付款方考量变化的影响。因此，医疗保健提供者和设备製造商优先考虑互通性、以患者为中心的结果指标以及能够带来可衡量临床价值的经济高效的途径。在这种动态变化中，策略性相关人员必须在短期营运调整与对临床试验、培训和跨学科合作的长期承诺之间取得平衡。本引言确立了后续章节中反映的基本趋势和战略要务，为深入探讨变革性转变、关税影响、细分市场细微差别、区域差异、竞争定位以及为致力于塑造介入肿瘤学未来的领导者提供的可行建议奠定了基础。

技术成熟度、临床证据产生和伙伴关係模式如何重塑介入肿瘤学的治疗模式、训练计划和商业策略

介入性肿瘤学领域正在经历变革，迫使人们重新思考临床路径、商业策略和研究重点。微型器械、能量传递系统和栓塞材料的进步扩展了临床应用范围，使以往不切实际或高风险的手术成为可能。因此，微创消融切除术越来越多地被纳入治疗体系，作为手术和全身性治疗的替代或补充，尤其适用于不适合手术的患者。

同时，影像和引导技术正变得越来越整合和复杂化，多重模式平台促进了即时程式回馈和更高的准确性。这种技术的成熟与更严格的临床范式同步进行。随机试验和大型多中心註册研究越来越多地为最佳实践提供信息，而基于价值的医疗倡议正在鼓励医疗服务提供者展示对患者和付款人重要的结果。

在商业性领域，设备製造商、诊断供应商和数位医疗公司之间建立的新型伙伴关係正在加速创建涵盖患者选择、治疗交付和长期追踪的端到端解决方案。因此，培训和认证已成为竞争优势，而卓越中心和设备专用课程正在塑造采用曲线。这些转变不仅改变了介入性肿瘤学的实践方式，也改变了研发、临床营运和上市职能部门如何协同合作，以抓住新的商机。

评估最近的关税调整如何影响全球采购成本结构、筹资策略以及临床环境中介入肿瘤设备的长期使用

美国实施的新贸易措施和关税调整为介入性肿瘤学供应链的相关人员带来了新的复杂性。关税对进口零件成本和成品定价产生了连锁反应，并对采购、库存管理和长期供应商合约产生了连锁反应。对于依赖跨境製造地或专用零件的製造商而言，关税迫使他们重新评估筹资策略，并考虑资源配置以维持利润率和供应的连续性。

由于采购团队面临艰难的谈判，并寻求替代供应商以在不影响设备品质的情况下维持手术量，临床医生和医疗系统正在感受到下游影响。付款人和医院财务主管也在审查资本设备和一次性耗材的总拥有成本，更重视可证明的经济价值和明确的临床效益。关税导致的价格波动也促使企业加快成本控制倡议，包括可製造设计、组件标准化以及在可行的情况下进行策略性垂直整合。

此外，关税将透过改变各种治疗方法的相对成本效益来影响监管和报销计算。随着相关人员的适应，供应链、监管、临床和商业团队之间的跨职能协作对于降低风险和维持病患可及性至关重要。摘要，关税的发展将带来营运阻力和策略曲折点，迫使整个生态系统的相关人员追求有韧性的采购模式和基于证据的价值提案。

从产品系列、适应症、技术平台和最终用户的观点解构介入肿瘤学格局，以告知临床和商业优先事项

了解市场需要专注于产品系列、癌症类型、技术平台和最终用户概况。在产品领域，市场参与企业涉及消融设备、栓塞设备和支援设备。消融类别进一步细分为冷冻消融设备、高强度聚焦超音波和雷射系统；栓塞方法包括药物释放型珠和微球；支援产品包括导管导引线和导入套件等必需品。这些产品细分至关重要，因为它们决定了临床工作流程、资本投资模式和售后市场耗材需求，并构成了在特定肿瘤适应症中应用所需的证据基础。

癌症类型也决定了采用途径，大肠直肠癌、肾癌、肝癌和肺癌的临床实践有显着差异。每种肿瘤类型都有其自身的病变特征、典型的合併症特征和多学科管理模式，这些都会影响设备选择、手术时机和术后监测策略。近距离放射治疗、影像导航放射治疗、微波消融和射频消融在病灶大小相容性、邻近结构安全性和操作者学习曲线方面各有优缺点。

最后，门诊手术中心、癌症研究机构和医院的终端使用者格局决定了采购週期、报销介面和手术量。门诊中心通常重视吞吐效率和经济高效的抛弃式，研究机构优先考虑使用尖端平台和临床试验集成，而医院通常需要全面的支援、服务协议和企业级采购条款。全面了解这些细分市场，有助于相关人员更好地确定与研发重点、临床证据计画、应用驱动因素和组织约束相符的商业策略。

探讨全球不同地区不同的监管环境、报销环境和临床采用模式如何影响策略市场进入和扩张决策

区域动态对临床应用、监管途径、报销模式和供应链架构有着巨大的影响，了解这些差异对于有效地进入和拓展市场至关重要。在美洲，先进的手术网络、大量的手术量和完善的报销框架支持创新微创手术的快速普及，但成本控制压力和区域支付方差异使得针对个别患者进行量身定制的价值展示成为必要。在中东和非洲，监管的多样性和多样化的医疗资金筹措模式导致采用率参差不齐。

亚太地区的特点是医院基础设施投资快速成长、监管时间多样，以及精通微创肿瘤技术的临床医师团队不断壮大。这既带来了机会，也带来了独特的挑战。亚太地区既是许多医疗设备製造商的零件供应商，也是最终组装，因此跨境製造和分销策略尤其重要。由于临床指南、器械註册要求和患者转诊途径存在区域差异，因此需要製定量身定制的打入市场策略、本地化的证据生成以及与区域临床意见领袖的合作。

总的来说，区域洞察力可以为临床试验地点、监管提交和商业伙伴关係的优先排序提供信息，使公司能够以反映当地临床实践、付款人期望和物流现实的方式分配资源。

临床证据策略和策略伙伴关係提供的综合解决方案如何区分市场领导并塑造介入肿瘤学的竞争动态

介入肿瘤学领域的竞争态势由成熟的医疗科技公司、开发专用设备的创新者以及融合硬体和数位化能力的新兴参与企业共同塑造。规模较大的企业通常将广泛的产品系列组合与深厚的临床支持网络相结合，并在培训、证据生成和上市后监测方面进行投资，以保持差异化定位。而利基市场企业则专注于特定的手术类别或创新，并利用临床伙伴关係关係和有针对性的试验来建立信誉和临床偏好。

策略联盟和授权协议通常可以加速互补技术的获取，例如先进的影像迭加、导航系统和用于结果追踪的数位平台。此类联盟可以加快产品上市速度，同时实现涵盖整个临床路径而非单一程序步骤的整合解决方案。此外，对于希望扩大产品范围、进入相关肿瘤领域或整合供应链的公司而言，併购仍是一条可行的途径。

竞争对手之间的一个通用差异化因素是，他们能够用可靠的数据证明临床价值，并大规模培训外科医生和介入医生。那些将令人信服的临床证据与灵活的商业模式和强大的客户支援相结合的公司，往往能在大型中心和网路中获得优势。因此，长期的临床研究、对真实世界证据的投入以及对临床医生教育的持续投入，仍然是永续竞争优势的核心。

为设备製造商和临床网路提供可行的策略性倡议，以增强韧性、加速采用并展示整个医疗保健途径的经济和临床价值

为了应对当前复杂的市场并抓住临床发展机会，行业领导者应采取一系列切实可行的倡议。首先，透过投资模组化设备架构和可互通平台，简化流程生态系统并降低整体拥有成本，使产品开发蓝图与临床医生认为的未满足需求保持一致。同样重要的是，优先产生可靠的临床证据，以兼顾安全性和以患者为中心的治疗结果。这需要儘早与关键意见领袖沟通，并设计能够反映真实世界实践模式的临床试验。

第二，我们将采取弹性供应链策略，将多元化采购、关键零件的策略性库存缓衝以及区域製造相结合，以减轻关税和物流中断的影响。同时，我们将实施强调与付款人进行基于价值对话的商业模式，例如捆绑支付试点和在适当情况下基于结果的合同，以证明介入性肿瘤治疗的经济可行性。第三，我们将扩大临床医生培训和监考项目，将线下卓越中心与数位教育平台结合，以减少治疗结果的差异性，并加速患者对疗法的信心采纳。

最后，他们寻求有针对性的伙伴关係，将成像、导航和数据分析整合在一起，以提供超越单一程序价值提案的综合服务。透过同步研发、临床、供应链和商业策略，领导者可以改善患者的就诊机会并优化程序的有效性，同时建立可持续的差异化。

一种透明的、经临床医生检验的研究途径，将主要访谈特定证据综合与分析框架相结合，以确保严谨的见解和实际相关性

本研究整合了原始资料和二手资料，旨在对介入性肿瘤学领域进行全面而係统性的评估。原始资料研究包括对临床医生、采购负责人和临床营运负责人的结构化访谈，以检验操作流程、技术偏好和实施障碍。此外，我们还与行业和监管专家进行了交流，以了解核准途径和上市后预期，从而补充了这些定性见解。

二次研究利用同行评审的临床文献、主要肿瘤学和放射学协会的指南声明以及公开的监管文件，按设备类型绘製了证据趋势和安全信号。在适当的情况下，参考临床註册库和已发表的多中心系列研究来确定真实世界结局。技术白皮书和製造商文献也用于比较设备设计和特性。资料合成优先考虑跨多个资讯来源的交叉验证，并透过有针对性的后续访谈来协调差异。

我们采用的分析框架包括：細項分析（用于识别不同的应用驱动因素）、价值链映射（用于突出供应链的脆弱性）以及情境分析（用于探索应对监管和关税压力的策略性措施）。在整个研究过程中，我们强调资讯来源以及临床医生主导的检验，以确保我们的研究结果切实可行，并与当地实践紧密结合。

简明综合了临床进展的营运风险和策略要点，为相关人员追求永续成长和以病人为中心的成果的成功奠定了基础

总而言之，介入性肿瘤学正处于曲折点，技术进步、临床证据日趋成熟以及商业性压力不断演变，正在共同重塑治疗途径和市场策略。微创消融和栓塞疗法正日益被纳入多学科肿瘤治疗，并得到改进的影像引导和增强安全性和有效性的设备设计的支持。同时，贸易政策和区域监管差异等宏观因素要求我们制定灵活的供应链规划和区域打入市场策略。

成功的相关人员将拥有以下能力：以强有力的证据证明临床价值，建立可扩展的培训和支援模式以确保一致的疗效，并采用灵活的製造和采购安排来管理成本和连续性风险。将设备功能与影像、导航和数据分析相结合的策略伙伴关係关係，将进一步提升产品的差异化，并为医疗服务提供者和付款人提供更具吸引力的提案。总体而言，未来的道路将有利于那些将临床严谨性与营运韧性相结合，并明确关注以患者为中心的治疗结果的组织。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 基于基因生物标誌物的个人化药物释放型微球疗法在肝癌治疗的应用
  • 基于奈米技术的化学栓塞剂的开发，用于靶向药物传输并降低肝肿瘤的全身毒性
  • 机器人辅助微波消融系统的进步提高了手术效率和病变控制。
  • 采用冷冻治疗技术对摄护腺和肾臟肿瘤进行微创治疗，安全性较高
  • 基于查核点抑制剂的联合免疫栓塞策略的出现增强了局部和全身肿瘤反应
  • 即时成像与人工智慧导航结合，实现导管肿瘤栓塞前所未有的精度
  • 设备製造商与製药公司之间的策略伙伴关係关係推进下一代放射栓塞产品平臺

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 介入性肿瘤学市场（按产品）

  • 消融设备
    • 冷冻消融装置
    • 高强度聚焦超音波
    • 雷射系统
  • 栓塞装置
    • 药物释放型珠
    • 微球
  • 辅助器具
    • 导管导引线
    • 入门套件

9. 介入性肿瘤学市场（依癌症类型）

  • 大肠直肠癌
  • 肾癌
  • 肝癌
  • 肺癌

10. 介入性肿瘤学市场（依技术）

  • 近距离放射治疗
  • 影像导航放射治疗
  • 微波消融
  • 射频消融

第 11 章介入肿瘤学市场（依最终用户划分）

  • 门诊手术中心
  • 癌症研究所
  • 医院

12. 介入性肿瘤学市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章介入肿瘤学市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 介入性肿瘤学市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • ABK Biomedical Inc.
    • Accuray Incorporated
    • AngioDynamics, Inc.
    • Bayer AG
    • Boston Scientific Corporation
    • Cook Group Incorporated
    • Eckert & Ziegler BEBIG AG
    • Fujifilm Holdings Corporation
    • GE HealthCare Technologies Inc.
    • IceCure Medical Ltd.
    • Integer Holding Corporation
    • Johnson & Johnson Services, Inc.
    • Koninklijke Philips NV
    • Medtronic PLC
    • Merit Medical Systems, Inc.
    • Siemens Healthineers AG
    • Sirtex Medical Limited
    • Sonablate Corp
    • STARmed Co., Ltd.
    • Stryker Corporation
    • Surgnova Healthcare Technologies（Zhejiang）Co., Ltd.
    • Teleflex Incorporated
    • Terumo Corporation
    • Becton, Dickinson and Company
Product Code: MRR-43127F7279CE

The Interventional Oncology Market is projected to grow by USD 4.58 billion at a CAGR of 7.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.55 billion
Estimated Year [2025] USD 2.73 billion
Forecast Year [2032] USD 4.58 billion
CAGR (%) 7.58%

An authoritative orientation to the current interventional oncology ecosystem highlighting technological convergence clinical adoption and strategic imperatives

Interventional oncology has emerged as a critical pillar of multidisciplinary cancer care, driven by technological innovation, refined procedural techniques, and an expanding evidence base that supports less invasive, organ-preserving therapies. This introduction frames the broader landscape by highlighting the convergence of targeted device development, enhanced imaging modalities, and growing clinical acceptance across diverse tumor types. In recent years, clinicians have integrated ablative and embolic approaches into treatment algorithms, leveraging improvements in device precision and peri-procedural workflows to reduce morbidity while maintaining oncologic control.

Moreover, the industry is navigating an increasingly complex operating environment shaped by regulatory scrutiny, supply chain realignment, and shifting payer considerations. As a result, healthcare providers and device manufacturers are prioritizing interoperability, patient-centered outcome measurement, and cost-effective pathways that deliver measurable clinical value. Given these dynamics, strategic stakeholders must balance near-term operational adjustments with long-term commitments to clinical trials, training, and cross-disciplinary collaboration. Taken together, this introduction establishes the foundational trends and strategic imperatives that inform subsequent sections, setting the stage for a deep-dive into transformative shifts, tariff impacts, segmentation nuances, regional differentiators, competitive positioning, and actionable recommendations for leaders intent on shaping the future of interventional oncology.

How technological maturation clinical evidence generation and partnership models are reshaping treatment paradigms training initiatives and commercial strategies in interventional oncology

The interventional oncology landscape is undergoing transformative shifts that reframe clinical pathways, commercial strategies, and research priorities. Advances in device miniaturization, energy delivery systems, and embolic materials have expanded the clinical repertoire, enabling procedures that were previously impractical or high risk. As a result, the therapeutic continuum now more frequently incorporates minimally invasive ablative techniques as alternatives or complements to surgery and systemic therapy, particularly for patients who are poor surgical candidates.

Concurrently, imaging and guidance technologies have become more integrated and sophisticated, with multimodality platforms facilitating real-time procedural feedback and greater precision. This technological maturation is paralleled by more rigorous clinical frameworks: randomized trials and large multicenter registries are increasingly informing best practices, while value-based care initiatives push providers to demonstrate outcomes that matter to patients and payers. Regulatory pathways have adapted, yet remain exacting, prompting manufacturers to invest in robust evidence generation and post-market surveillance.

In the commercial arena, novel partnerships between device companies, diagnostic vendors, and digital health firms are accelerating the creation of end-to-end solutions that span patient selection, therapy delivery, and longitudinal follow-up. Training and credentialing have therefore become competitive differentiators, with centers of excellence and device-specific curricula shaping adoption curves. Taken together, these shifts not only change how interventional oncology is practiced but also how organizations must align R&D, clinical affairs, and go-to-market functions to capitalize on emerging opportunities.

Assessing how recent tariff adjustments are influencing global sourcing cost structures procurement strategies and long term access to interventional oncology devices in clinical practice

The imposition of new trade measures and tariff adjustments in the United States has introduced an additional layer of complexity for stakeholders in the interventional oncology supply chain. Tariff actions affect inbound component costs and finished device pricing in ways that reverberate across procurement, inventory management, and long-term supplier contracts. For manufacturers that rely on cross-border manufacturing footprints and specialized components, tariffs have prompted reassessments of sourcing strategies and incremental reshoring considerations to preserve margin and supply continuity.

Clinicians and health systems feel the downstream effects as procurement teams face tighter negotiations and seek alternative suppliers to maintain procedural volumes without compromising equipment quality. In turn, payers and hospital finance leaders examine the total cost of ownership for capital equipment and single-use disposables, amplifying the emphasis on demonstrable economic value and clear clinical benefit. Tariff-driven price volatility also incentivizes manufacturers to accelerate cost-control initiatives, such as design for manufacturability, component standardization, and strategic vertical integration where feasible.

Furthermore, tariffs influence the regulatory and reimbursement calculus by altering the relative cost-effectiveness of different therapeutic modalities. As stakeholders adapt, cross-functional collaboration between supply chain, regulatory, clinical, and commercial teams becomes essential to mitigate risk and maintain patient access. In summary, tariff developments create both operational headwinds and strategic inflection points, compelling actors across the ecosystem to pursue resilient sourcing models and evidence-based value propositions.

Deconstructing the interventional oncology landscape through product tumor indication technology platform and end user perspectives to inform clinical and commercial priorities

Understanding the market requires attention to product families, cancer types, technology platforms, and end-user profiles, each of which carries distinct clinical and commercial implications. Within the product domain, market participants engage across ablation devices, embolization devices, and supportive devices; the ablation category is differentiated further into cryoablation devices, high-intensity focused ultrasound, and laser systems, while embolization approaches include drug-eluting beads and microspheres and supportive products encompass essential items such as guidewires and introduction kits. These product distinctions matter because they determine clinical workflows, capital expenditure patterns, and aftermarket consumable demand, and they also shape the evidence required for adoption in particular tumor indications.

Cancer type segmentation likewise underpins adoption pathways, with clinical practice varying substantially across colorectal cancer, kidney cancer, liver cancer, and lung cancer. Each tumor type has its own lesion characteristics, typical comorbidity profiles, and multidisciplinary management patterns, which in turn influence device selection, procedural timing, and post-procedure surveillance strategies. Technology segmentation further refines clinical decision-making: brachytherapy, image-guided radiotherapy, microwave ablation, and radiofrequency ablation each bring unique advantages and trade-offs in terms of lesion size suitability, adjacent structure safety, and operator learning curves.

Finally, the end-user landscape-spanning ambulatory surgical centers, cancer research institutes, and hospitals-dictates purchasing cycles, reimbursement interfaces, and procedural volumes. Ambulatory centers often value throughput efficiency and cost-effective disposables, research institutes prioritize access to cutting-edge platforms and clinical trial integration, while hospitals typically require comprehensive support, service agreements, and enterprise-level procurement terms. By synthesizing these segmentation lenses, stakeholders can better prioritize R&D focus, clinical evidence plans, and commercial tactics that align with adoption drivers and institutional constraints.

Exploring how divergent regulatory landscapes reimbursement environments and clinical adoption patterns across global regions shape strategic market entry and expansion decisions

Regional dynamics exert a powerful influence on clinical adoption, regulatory pathways, reimbursement models, and supply chain architecture, and understanding these differences is essential for effective market entry and expansion. In the Americas, advanced procedural networks, high procedural volumes, and established reimbursement frameworks support rapid uptake of innovative minimally invasive therapies, although cost containment pressures and regional payer variability require tailored value demonstrations. In Europe Middle East and Africa, regulatory heterogeneity and divergent healthcare financing models produce a mosaic of adoption rates; meanwhile, centers of excellence in major European metropolitan areas drive innovation adoption that then diffuses asynchronously across the broader region.

The Asia Pacific region presents both opportunities and distinct challenges, characterized by rapid investment in hospital infrastructure, divergent regulatory timelines, and an expanding pool of clinicians trained in minimally invasive oncology techniques. Cross-border manufacturing and distribution strategies are particularly relevant to Asia Pacific given its role in both component supply and final assembly for many device makers. Across regions, differences in clinical guidelines, device registration requirements, and patient referral pathways demand bespoke market access strategies, localized evidence generation, and partnerships with regional clinical opinion leaders.

Taken together, regional insights inform prioritization of clinical trial sites, regulatory submissions, and commercial partnerships, enabling companies to allocate resources in ways that reflect local clinical practice, payer expectations, and logistical realities.

How strategic partnerships clinical evidence strategies and integrated solution offerings are differentiating market leaders and shaping competitive dynamics in interventional oncology

Competitive dynamics in interventional oncology are shaped by a mix of established medtech firms, specialized device innovators, and emerging entrants that combine hardware with digital capabilities. Leading organizations typically blend broad product portfolios with deep clinical support networks, investing in training, evidence generation, and post-market surveillance to maintain differentiated positioning. Meanwhile, niche manufacturers focus on specific procedural categories or technological innovations, using clinical partnerships and targeted trials to build credibility and clinical preference.

Strategic collaborations and licensing arrangements often accelerate access to complementary technologies such as advanced imaging overlays, navigation systems, and digital platforms for outcomes tracking. These partnerships can reduce time to market while enabling integrated solutions that address entire clinical pathways rather than isolated procedural steps. In addition, mergers and acquisitions remain a pragmatic route for companies seeking to augment product breadth, enter adjacent tumor segments, or consolidate supply chains.

Across the competitive spectrum, a common differentiator is the ability to demonstrate clinical value through robust data and to operationalize surgeon and interventionalist training at scale. Companies that couple compelling clinical evidence with flexible commercial models and strong customer support tend to secure preferred status within high-volume centers and networks. As a result, ongoing investment in long-term clinical studies, real-world evidence initiatives, and clinician education remains central to sustainable competitive advantage.

Actionable strategic initiatives for device manufacturers and clinical networks to strengthen resilience accelerate adoption and demonstrate economic and clinical value across care pathways

Industry leaders should pursue a set of pragmatic, actionable initiatives to navigate current market complexities and capitalize on clinical momentum. First, align product development roadmaps with clinician-identified unmet needs by investing in modular device architectures and interoperable platforms that simplify the procedural ecosystem and reduce total cost of ownership. Equally important is to prioritize robust clinical evidence generation that addresses both safety and patient-centered outcomes; this requires early engagement with key opinion leaders and designing trials that reflect real-world practice patterns.

Second, adopt resilient supply chain strategies that combine diversified sourcing, strategic inventory buffers for critical components, and selective regional manufacturing to mitigate tariff exposure and logistics disruptions. In parallel, implement commercial models that emphasize value-based conversations with payers, including bundled payment pilots and outcomes-based contracting where appropriate, to demonstrate the economic case for interventional oncology therapies. Third, scale clinician training and proctoring programs through a mix of in-person centers of excellence and digital education platforms to reduce variability in outcomes and accelerate confident adoption.

Finally, pursue targeted partnerships that integrate imaging, navigation, and data analytics, thereby creating holistic offerings that extend beyond single-procedure value propositions. By synchronizing R&D, clinical affairs, supply chain, and commercial strategy, leaders can build durable differentiation while improving patient access and optimizing procedural efficacy.

A transparent and clinician validated research approach combining primary interviews evidence synthesis and analytical frameworks to ensure rigorous insights and practical relevance

This research synthesizes primary and secondary sources to produce a comprehensive, methodical assessment of the interventional oncology landscape. Primary research included structured interviews with clinicians, procurement officers, and clinical operations leaders to validate procedural workflows, technology preferences, and adoption barriers. These qualitative insights were complemented by engagement with industry experts and regulatory specialists to understand approval pathways and post-market surveillance expectations.

Secondary research drew on peer-reviewed clinical literature, guideline statements from leading oncology and radiology societies, and publicly available regulatory filings to map evidence trends and safety signals across device types. Where appropriate, clinical registries and published multicenter series were referenced to contextualize real-world outcomes, while technical whitepapers and manufacturer literature informed device design and feature comparisons. Data synthesis prioritized cross-validation across multiple sources and reconciliation of discrepancies through targeted follow-up interviews.

Analytical frameworks employed include segmentation analysis to identify differential adoption drivers, value chain mapping to highlight supply chain vulnerabilities, and scenario analysis to explore strategic responses to regulatory and tariff pressures. Throughout the research process, emphasis was placed on transparency of sources, rigor in evidence appraisal, and the use of clinician-led validation to ensure findings are actionable and closely aligned with frontline practice.

A concise synthesis of clinical advances operational risks and strategic imperatives that define success for stakeholders pursuing sustainable growth and patient centered outcomes

In conclusion, interventional oncology stands at an inflection point where technological progress, clinical evidence maturation, and evolving commercial pressures converge to redefine care pathways and market strategies. Minimally invasive ablative and embolic therapies are increasingly integrated into multidisciplinary oncology care, supported by improvements in imaging guidance and device design that enhance safety and efficacy. At the same time, macro factors such as trade policies and regional regulatory variability require nimble supply chain planning and localized market access strategies.

Stakeholders who succeed will be those that demonstrate clinical value through robust evidence, build scalable training and support models to ensure consistent outcomes, and adopt flexible manufacturing and sourcing arrangements to manage cost and continuity risks. Strategic partnerships that link device capabilities with imaging, navigation, and data analytics will further differentiate offerings and create more compelling propositions for providers and payers. Overall, the path forward favors organizations that combine clinical rigor with operational resilience and a clear focus on patient-centered outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of personalized drug-eluting microsphere therapies guided by genomic biomarkers for liver cancer treatment
  • 5.2. Development of nanotechnology-based chemoembolic agents for targeted drug delivery and reduced systemic toxicity in liver tumors
  • 5.3. Advancements in robotic-assisted microwave ablation systems enhancing procedural efficiency and lesion control in interventional oncology
  • 5.4. Adoption of cryoablation techniques in minimally invasive treatment of prostate and renal tumors with enhanced safety profiles
  • 5.5. Emergence of combined immunoembolization strategies leveraging checkpoint inhibitors to boost local and systemic tumor response
  • 5.6. Integration of real-time imaging and AI-enabled navigation in catheter-based tumor embolization achieving unprecedented precision
  • 5.7. Strategic partnerships between device manufacturers and pharma companies driving next-generation radioembolization product pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Interventional Oncology Market, by Product

  • 8.1. Ablation Devices
    • 8.1.1. Cryoablation Devices
    • 8.1.2. High-Intensity Focused Ultrasound
    • 8.1.3. Laser Systems
  • 8.2. Embolization Devices
    • 8.2.1. Drug-Eluting Beads
    • 8.2.2. Microspheres
  • 8.3. Supportive Devices
    • 8.3.1. Guidewires
    • 8.3.2. Introduction Kits

9. Interventional Oncology Market, by Cancer Type

  • 9.1. Colorectal Cancer
  • 9.2. Kidney Cancer
  • 9.3. Liver Cancer
  • 9.4. Lung Cancer

10. Interventional Oncology Market, by Technology

  • 10.1. Brachytherapy
  • 10.2. Image-Guided Radiotherapy
  • 10.3. Microwave Ablation
  • 10.4. Radiofrequency Ablation

11. Interventional Oncology Market, by End-User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cancer Research Institutes
  • 11.3. Hospitals

12. Interventional Oncology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Interventional Oncology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Interventional Oncology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. ABK Biomedical Inc.
    • 15.3.3. Accuray Incorporated
    • 15.3.4. AngioDynamics, Inc.
    • 15.3.5. Bayer AG
    • 15.3.6. Boston Scientific Corporation
    • 15.3.7. Cook Group Incorporated
    • 15.3.8. Eckert & Ziegler BEBIG AG
    • 15.3.9. Fujifilm Holdings Corporation
    • 15.3.10. GE HealthCare Technologies Inc.
    • 15.3.11. IceCure Medical Ltd.
    • 15.3.12. Integer Holding Corporation
    • 15.3.13. Johnson & Johnson Services, Inc.
    • 15.3.14. Koninklijke Philips N.V.
    • 15.3.15. Medtronic PLC
    • 15.3.16. Merit Medical Systems, Inc.
    • 15.3.17. Siemens Healthineers AG
    • 15.3.18. Sirtex Medical Limited
    • 15.3.19. Sonablate Corp
    • 15.3.20. STARmed Co., Ltd.
    • 15.3.21. Stryker Corporation
    • 15.3.22. Surgnova Healthcare Technologies (Zhejiang) Co., Ltd.
    • 15.3.23. Teleflex Incorporated
    • 15.3.24. Terumo Corporation
    • 15.3.25. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INTERVENTIONAL ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INTERVENTIONAL ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CRYOABLATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CRYOABLATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CRYOABLATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CRYOABLATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CRYOABLATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CRYOABLATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LASER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LASER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LASER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY DRUG-ELUTING BEADS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY DRUG-ELUTING BEADS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY DRUG-ELUTING BEADS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY DRUG-ELUTING BEADS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY DRUG-ELUTING BEADS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY DRUG-ELUTING BEADS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GUIDEWIRES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GUIDEWIRES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GUIDEWIRES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GUIDEWIRES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY INTRODUCTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY INTRODUCTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY INTRODUCTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY INTRODUCTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY INTRODUCTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY INTRODUCTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY KIDNEY CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY KIDNEY CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY KIDNEY CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY KIDNEY CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY IMAGE-GUIDED RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROWAVE ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROWAVE ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROWAVE ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY MICROWAVE ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL INTERVENTIONAL ONCOLOGY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 296. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 297. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 298. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 299. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY EMBOLIZATION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 302. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 303. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC INTERVENTIONAL ONCOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLATION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION INTERVENTIONAL ONCOLOGY MARKET SIZE, BY ABLA